Holgate S T, Bradding P, Sampson A P
Faculty of Medicine, Southampton General Hospital, England.
J Allergy Clin Immunol. 1996 Jul;98(1):1-13. doi: 10.1016/s0091-6749(96)70220-8.
This article briefly reviews the advances in our understanding of asthma with a particular focus on the role of inflammation, before providing a concise overview of current knowledge of leukotrienes in the pathophysiology of the disease. The development of leukotriene receptor antagonists and synthesis inhibitors in briefly described; and acute exercise, allergen, and aspirin challenge studies with these agents are reviewed. Clinical studies with leukotriene antagonists and inhibitors have confirmed the central role of leukotrienes in asthma pathophysiology. In conclusion, we suggest that the new generation of leukotriene receptor antagonists may be suitable as first-line therapy in patients with mild to moderate asthma. Further studies are required to determine whether the leukotriene synthesis inhibitors will be equally effective or provide any additional antiinflammatory benefit.
本文简要回顾了我们对哮喘认识的进展，特别关注炎症的作用，然后简要概述了目前关于白三烯在该疾病病理生理学中的知识。简要描述了白三烯受体拮抗剂和合成抑制剂的发展情况；并综述了使用这些药物进行的急性运动、过敏原和阿司匹林激发试验研究。白三烯拮抗剂和抑制剂的临床研究证实了白三烯在哮喘病理生理学中的核心作用。总之，我们认为新一代白三烯受体拮抗剂可能适合作为轻至中度哮喘患者的一线治疗药物。需要进一步研究以确定白三烯合成抑制剂是否同样有效或是否能提供任何额外的抗炎益处。
